PL-BIOSCIENCE-GMBH
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.
In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases; from standard laboratory research to GMP cell therapies. From academic research, pre-clinical research, and cell therapy, the high quality GMP compliant standards of ELAREM™ ensures seamless transitions of regenerative medicine breakthroughs – from the lab to patients in need.
About Macopharma
Founded in 1977, Macopharma is a major player in the medical devices industry in the blood sector. Based in Tourcoing, in the North of France (59), its development has always been driven by important innovations, results of investments made in research and development and collaborations customers and partners (blood transfusion centers, research laboratories, hospitals...). For all these activities, Macopharma offers a range of solutions that respond to each step of the process from donor to patient.
With more than 2000 employees, 3 plants (in France, Poland and Tunisia) and a presence in nearly 100 countries worldwide, Macopharma's vision is to provide sustainable products and integrated services to ensure safe and secured blood component solutions to every patient in the world.
For more information, visit macopharma.com and follow Linkedin MACOPHARMA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
Aptiv Powers Intelligent Edge Applications From Automotive to Robotics at CES 20265.1.2026 07:01:00 CET | Press release
Showcase Features Aptiv Technologies Enabling Intelligent Cars, Commercial Vehicles, Robots, and Other Mission Critical ApplicationsImmersive Demos Highlight End-to-End AI for Autonomy, Personalized User Experience and Extensive Connectivity Aptiv PLC (NYSE: APTV),a global industrial technology company, will showcase at CES 2026 how its intelligent edge solutions enable devices to sense, think, and act in real time—while continuously optimizing performance throughout their lifecycle. This approach brings advanced computing and artificial intelligence closer to where data is generated, unlocking AI-driven solutions for transportation, robotics, aerospace, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104888341/en/ Aptiv Powers the Intelligent Edge from Automotive to Robotics at CES 2026 By processing data locally at the edge, rather than relying solely on centralized cloud systems, Aptiv’s solutions enable fas
Belkin styrker beskyttelsen af hverdagsenheder med en ny serie skærmbeskyttere og et Wear & Tear-program4.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer syv nye skærmbeskyttere, der er udviklet med proprietær Nano-Titan-teknologi for øget styrke mod daglige fald og ridser Et Wear and Tear-program skaber ro i sindet for forbrugere, der ønsker at udskifte deres produkter Forbrugerne kan nu personalisere deres skærmbeskyttere med Screen Skinz Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerer i dag en ny klasse af løsninger til skærmbeskyttelse, et strategisk partnerskab og et helt nyt wear-and-tear-program, der styrker virksomhedens engagement i at beskytte enheder og give forbrugerne tryghed. Lanceringen omfatter syv nye skærmbeskyttere, et partnerskab med ScreenSkinz vedrørende personalisering, og et program til udskiftning af skærmbeskyttere beregnet til at give brugerne varig ro i sindet og sikre, at de produkter, de elsker, forbliver trygge, sikre og i den bedste form. Mød ScreenForce Titan-serien: Det ultimative inden for fuldskærmsbeskyttelse Titan SmartShield Titan SmartShield fungerer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom